Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.
What happened
FDA inspected Seatex's drug manufacturing facility in Rosenberg, Texas, from October 16 to October 20, 2023. FDA found OTC hand sanitizer made on equipment also used for non-pharmaceutical products such as floor cleaner without cleaning validation, inadequate investigations and records for failing test results, and no identity testing or methanol, diethylene glycol (DEG), or ethylene glycol (EG) limits for incoming ethanol and glycerin. After a February 8, 2024 teleconference, the company recalled four products on February 19, 2024; FDA found the November 3, 2023 response inadequate.
What FDA found
Made OTC hand sanitizer on equipment also used for industrial chemicals such as floor cleaner without cleaning validation studies.
21 CFR 211.67(b)Failed to properly investigate out-of-specification test results and did not record or retain failing results.
21 CFR 211.192Did not perform identity testing for incoming components such as ethanol and glycerin, and did not test ethanol for methanol or glycerin for diethylene glycol (DEG) or ethylene glycol (EG).
21 CFR 211.84(d)(1) and 211.84(d)(2)Quality control unit lacked authority and records to ensure CGMP compliance, including missing equipment, water system, and process validation records.
21 CFR 211.22
What FDA wants
Respond in writing within 15 working days with what you have done to correct violations and prevent recurrence, and clarify whether you intend to resume drug manufacturing and notify FDA before doing so.
Who should pay attention
- manufacturers of OTC hand sanitizers
- companies sharing equipment between drugs and industrial products
- drugmakers relying on supplier certificates for ethanol or glycerin
This is a summary. Read the original letter on fda.gov.